IMPACT Therapeutics
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Series A | ||
$10.0m | Series B | ||
$30.0m | Series C | ||
$50.0m | Series C | ||
* | N/A | Series D | |
* | $55.3m Valuation: $691m | Series D | |
Total Funding | €132m |
Related Content
Recent News about IMPACT Therapeutics
EditImpact Therapeutics is a biopharmaceutical company focused on developing innovative cancer therapies. The company operates in the oncology market, targeting both patients and healthcare providers. Its business model revolves around the discovery and clinical translation of novel drugs designed to treat various forms of cancer. By integrating drug discovery with clinical trials, Impact Therapeutics aims to bring effective treatments to market more efficiently. The company generates revenue through partnerships, licensing agreements, and the commercialization of its proprietary drugs. Key clients include hospitals, cancer treatment centers, and pharmaceutical companies. Impact Therapeutics leverages its expertise in personalized cancer therapy to improve patient outcomes and advance the field of oncology.
Keywords: cancer therapy, drug discovery, clinical trials, oncology, biopharmaceutical, personalized medicine, healthcare, innovation, patient outcomes, partnerships.